Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "FDA"

2490 News Found

AngioDynamics gets FDA nod for RELIEF trial to evaluate NanoKnife for enlarged prostate treatment
Medical Device | June 19, 2026

AngioDynamics gets FDA nod for RELIEF trial to evaluate NanoKnife for enlarged prostate treatment

Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)


AbbVie's Allergan wins FDA nod for first injectable targeting neck lines
Drug Approval | June 18, 2026

AbbVie's Allergan wins FDA nod for first injectable targeting neck lines

The newly approved treatment, SKINVIVE by JUVÉDERM, is now the first and only hyaluronic acid injectable cleared specifically for improving neck appearance


FDA clears Dexcom’s Stelo as first OTC Continuous Glucose Monitor for kids
Medical Device | June 16, 2026

FDA clears Dexcom’s Stelo as first OTC Continuous Glucose Monitor for kids

Expanded indication makes Stelo the first FDA-cleared OTC CGM for children aged two years and older with diabetes or prediabetes


Roche wins FDA approval for first PTEN-loss companion diagnostic in prostate cancer
News | June 16, 2026

Roche wins FDA approval for first PTEN-loss companion diagnostic in prostate cancer

The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer


Alembic secures USFDA nod for Tretinoin Cream strengthening generics portfolio
Drug Approval | June 14, 2026

Alembic secures USFDA nod for Tretinoin Cream strengthening generics portfolio

The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream


FDA clears Wave Neuroscience’s AI-guided brain stimulation platform for PTSD treatment
Medical Device | June 13, 2026

FDA clears Wave Neuroscience’s AI-guided brain stimulation platform for PTSD treatment

MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms


Ryvu advances romaciclib program as FDA clears AML trial expansion
Clinical Trials | June 13, 2026

Ryvu advances romaciclib program as FDA clears AML trial expansion

The regulatory decision follows promising results from RIVER-81


Alembic Pharma receives USFDA tentative approval for generic Larotrectinib capsules
Drug Approval | June 11, 2026

Alembic Pharma receives USFDA tentative approval for generic Larotrectinib capsules

Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.


FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough
R&D | June 10, 2026

FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough

The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year


FDA expands Pfizer’s HYMPAVZI approval
Drug Approval | June 09, 2026

FDA expands Pfizer’s HYMPAVZI approval

Broadening access for children & patients with inhibitor-complicated hemophilia